744 related articles for article (PubMed ID: 28237701)
1. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer.
Chung SY; Jung YY; Park IA; Kim H; Chung YR; Kim JY; Park SY; Im SA; Lee KH; Moon HG; Noh DY; Han W; Lee C; Kim TY; Ryu HS
Clin Exp Metastasis; 2016 Feb; 33(2):179-85. PubMed ID: 26585892
[TBL] [Abstract][Full Text] [Related]
5. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
[TBL] [Abstract][Full Text] [Related]
6. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
7. FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer.
Rehman A; Kim Y; Kim H; Sim J; Ahn H; Chung MS; Shin SJ; Jang K
J Clin Pathol; 2018 Sep; 71(9):806-813. PubMed ID: 29588373
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Cystatin E/M with Clinicopathological Features and Prognosis in Triple-Negative Breast Cancer.
Li Q; Zheng ZC; Ni CJ; Jin WX; Jin YX; Chen Y; Zhang XH; Chen ED; Cai YF
Ann Clin Lab Sci; 2018 Jan; 48(1):40-44. PubMed ID: 29530995
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers.
Wang J; Song Y; Liu T; Shi Q; Zhong Z; Wei W; Huang S; Pang D
Tumour Biol; 2015 Jun; 36(6):4793-9. PubMed ID: 25794640
[TBL] [Abstract][Full Text] [Related]
10. Clinical implication of leucine zipper/EF hand-containing transmembrane-1 overexpression in the prognosis of triple-negative breast cancer.
Wang CA; Liu Q; Chen Y; Liu S; Xu J; Cui X; Zhang Y; Piao L
Exp Mol Pathol; 2015 Apr; 98(2):254-9. PubMed ID: 25617527
[TBL] [Abstract][Full Text] [Related]
11. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
12. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
13. [Expression and clinical significance of MTDH and VEGF in triple-negative breast cancer].
Tan L; Qin H; Piao Y; Liu Z; Han Y; Song F; Xie X
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):827-32. PubMed ID: 26887512
[TBL] [Abstract][Full Text] [Related]
14. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
15. CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
Pedersen MH; Hood BL; Ehmsen S; Beck HC; Conrads TP; Bak M; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2019 Feb; 144(3):631-640. PubMed ID: 30110125
[TBL] [Abstract][Full Text] [Related]
16. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
[TBL] [Abstract][Full Text] [Related]
18. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
19. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
20. Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer.
Zhao Q; Xu WT; Shalieer T
Dis Markers; 2016; 2016():2325987. PubMed ID: 27843173
[No Abstract] [Full Text] [Related]
[Next] [New Search]